Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 30 | 2025 | 432 | 5.530 |
Why?
|
| Anti-HIV Agents | 16 | 2025 | 102 | 3.850 |
Why?
|
| Pre-Exposure Prophylaxis | 16 | 2025 | 67 | 2.950 |
Why?
|
| Contraceptive Devices, Female | 12 | 2025 | 13 | 2.780 |
Why?
|
| HIV-1 | 4 | 2023 | 36 | 1.850 |
Why?
|
| Young Adult | 31 | 2026 | 567 | 1.590 |
Why?
|
| Female | 51 | 2026 | 4060 | 1.590 |
Why?
|
| Pyrimidines | 7 | 2025 | 17 | 1.510 |
Why?
|
| Humans | 64 | 2026 | 6794 | 1.500 |
Why?
|
| Adolescent | 30 | 2026 | 869 | 1.370 |
Why?
|
| Uveitis | 7 | 2019 | 53 | 1.230 |
Why?
|
| Adult | 31 | 2025 | 2113 | 1.160 |
Why?
|
| Drug Overdose | 7 | 2025 | 15 | 1.090 |
Why?
|
| South Africa | 14 | 2025 | 68 | 1.040 |
Why?
|
| Intimate Partner Violence | 6 | 2025 | 10 | 1.040 |
Why?
|
| Patient Preference | 6 | 2025 | 11 | 0.980 |
Why?
|
| Substance Abuse, Intravenous | 5 | 2025 | 17 | 0.940 |
Why?
|
| Male | 32 | 2026 | 3671 | 0.860 |
Why?
|
| Substance-Related Disorders | 4 | 2025 | 102 | 0.800 |
Why?
|
| Surveys and Questionnaires | 8 | 2025 | 280 | 0.760 |
Why?
|
| Mycophenolic Acid | 3 | 2016 | 7 | 0.740 |
Why?
|
| Methotrexate | 3 | 2016 | 11 | 0.740 |
Why?
|
| Zimbabwe | 10 | 2025 | 12 | 0.740 |
Why?
|
| Immunosuppressive Agents | 3 | 2016 | 31 | 0.730 |
Why?
|
| Antimetabolites | 2 | 2017 | 6 | 0.640 |
Why?
|
| Pregnancy | 9 | 2026 | 599 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2025 | 72 | 0.580 |
Why?
|
| Cross-Over Studies | 5 | 2024 | 27 | 0.540 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 28 | 0.490 |
Why?
|
| Medication Adherence | 3 | 2025 | 64 | 0.480 |
Why?
|
| Pregnancy in Adolescence | 2 | 2026 | 5 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2025 | 153 | 0.470 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2026 | 35 | 0.460 |
Why?
|
| Criminal Law | 2 | 2025 | 6 | 0.450 |
Why?
|
| Middle Aged | 16 | 2025 | 2108 | 0.450 |
Why?
|
| Needle-Exchange Programs | 3 | 2025 | 5 | 0.450 |
Why?
|
| Analgesics, Opioid | 3 | 2025 | 58 | 0.430 |
Why?
|
| Opioid-Related Disorders | 2 | 2025 | 17 | 0.430 |
Why?
|
| Contraception | 4 | 2022 | 7 | 0.380 |
Why?
|
| Choice Behavior | 5 | 2025 | 11 | 0.370 |
Why?
|
| Depression | 2 | 2026 | 128 | 0.370 |
Why?
|
| Visual Acuity | 5 | 2019 | 123 | 0.350 |
Why?
|
| United States | 9 | 2025 | 1019 | 0.350 |
Why?
|
| California | 7 | 2026 | 230 | 0.330 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 2 | 2020 | 3 | 0.310 |
Why?
|
| Patient Compliance | 2 | 2020 | 48 | 0.300 |
Why?
|
| Uganda | 6 | 2025 | 20 | 0.300 |
Why?
|
| Tenofovir | 3 | 2025 | 9 | 0.290 |
Why?
|
| Kenya | 6 | 2025 | 9 | 0.280 |
Why?
|
| Longitudinal Studies | 5 | 2026 | 140 | 0.280 |
Why?
|
| Social Stigma | 2 | 2025 | 58 | 0.280 |
Why?
|
| Mental Health | 2 | 2026 | 70 | 0.270 |
Why?
|
| Vaccination | 2 | 2025 | 49 | 0.270 |
Why?
|
| Panuveitis | 2 | 2017 | 3 | 0.250 |
Why?
|
| Fentanyl | 2 | 2023 | 7 | 0.250 |
Why?
|
| Quality of Life | 2 | 2019 | 184 | 0.240 |
Why?
|
| Sexual Health | 1 | 2026 | 3 | 0.240 |
Why?
|
| Drug Users | 2 | 2024 | 4 | 0.230 |
Why?
|
| Transgender Persons | 1 | 2025 | 24 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 64 | 0.230 |
Why?
|
| Qualitative Research | 2 | 2023 | 82 | 0.230 |
Why?
|
| Disease Transmission, Infectious | 1 | 2025 | 7 | 0.230 |
Why?
|
| Chemoprevention | 1 | 2025 | 9 | 0.230 |
Why?
|
| Indians, North American | 1 | 2025 | 5 | 0.230 |
Why?
|
| Bullying | 1 | 2025 | 9 | 0.230 |
Why?
|
| Sexual Behavior | 2 | 2025 | 100 | 0.230 |
Why?
|
| Racism | 1 | 2026 | 49 | 0.230 |
Why?
|
| Gender-Based Violence | 1 | 2025 | 3 | 0.230 |
Why?
|
| Crime Victims | 1 | 2025 | 16 | 0.230 |
Why?
|
| Sex Offenses | 1 | 2025 | 5 | 0.230 |
Why?
|
| Ecological Momentary Assessment | 1 | 2025 | 1 | 0.230 |
Why?
|
| Peer Group | 1 | 2025 | 34 | 0.220 |
Why?
|
| Schools | 2 | 2025 | 25 | 0.220 |
Why?
|
| Law Enforcement | 1 | 2024 | 5 | 0.220 |
Why?
|
| Risk Factors | 6 | 2025 | 767 | 0.220 |
Why?
|
| Anxiety | 2 | 2026 | 35 | 0.210 |
Why?
|
| Administration, Oral | 5 | 2025 | 54 | 0.210 |
Why?
|
| San Francisco | 4 | 2025 | 13 | 0.210 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 145 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 5 | 0.200 |
Why?
|
| Smoking | 3 | 2023 | 86 | 0.200 |
Why?
|
| Contraceptive Agents | 1 | 2023 | 2 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2023 | 26 | 0.190 |
Why?
|
| Domestic Violence | 1 | 2022 | 2 | 0.190 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 65 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2025 | 331 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 506 | 0.180 |
Why?
|
| Soft Tissue Infections | 1 | 2022 | 7 | 0.180 |
Why?
|
| Health Promotion | 1 | 2022 | 89 | 0.180 |
Why?
|
| Adolescent Behavior | 1 | 2022 | 43 | 0.180 |
Why?
|
| Drug Implants | 1 | 2021 | 16 | 0.180 |
Why?
|
| Residence Characteristics | 4 | 2022 | 36 | 0.170 |
Why?
|
| Crime | 1 | 2021 | 7 | 0.170 |
Why?
|
| Health Status | 2 | 2019 | 83 | 0.160 |
Why?
|
| Vagina | 1 | 2020 | 14 | 0.160 |
Why?
|
| Menstruation | 1 | 2020 | 3 | 0.160 |
Why?
|
| Hygiene | 1 | 2020 | 2 | 0.160 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 10 | 0.150 |
Why?
|
| Heroin Dependence | 1 | 2018 | 3 | 0.140 |
Why?
|
| Binge Drinking | 1 | 2018 | 4 | 0.140 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2018 | 4 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 9 | 0.140 |
Why?
|
| Fluprednisolone | 1 | 2018 | 1 | 0.140 |
Why?
|
| Georgia | 3 | 2025 | 5 | 0.140 |
Why?
|
| North Carolina | 3 | 2025 | 4 | 0.140 |
Why?
|
| Administration, Intravaginal | 3 | 2024 | 4 | 0.140 |
Why?
|
| Macula Lutea | 1 | 2018 | 6 | 0.140 |
Why?
|
| Research Subjects | 1 | 2018 | 7 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2017 | 6 | 0.130 |
Why?
|
| Uveitis, Posterior | 1 | 2017 | 8 | 0.130 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 268 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2016 | 25 | 0.130 |
Why?
|
| Scleritis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2016 | 12 | 0.120 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 18 | 0.120 |
Why?
|
| Uveomeningoencephalitic Syndrome | 1 | 2016 | 7 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 53 | 0.120 |
Why?
|
| Registries | 1 | 2016 | 63 | 0.120 |
Why?
|
| Agriculture | 2 | 2026 | 3 | 0.120 |
Why?
|
| Aged | 4 | 2025 | 1539 | 0.110 |
Why?
|
| Prevalence | 2 | 2025 | 259 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2018 | 681 | 0.110 |
Why?
|
| Alabama | 2 | 2025 | 9 | 0.110 |
Why?
|
| Naloxone | 2 | 2024 | 22 | 0.100 |
Why?
|
| Narcotic Antagonists | 2 | 2024 | 29 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2025 | 23 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2025 | 89 | 0.100 |
Why?
|
| Social Environment | 2 | 2022 | 17 | 0.090 |
Why?
|
| Pregnancy, Unplanned | 2 | 2022 | 4 | 0.090 |
Why?
|
| Counseling | 2 | 2022 | 29 | 0.090 |
Why?
|
| Syringes | 2 | 2022 | 4 | 0.090 |
Why?
|
| Homosexuality, Male | 2 | 2025 | 83 | 0.090 |
Why?
|
| Economics, Behavioral | 2 | 2023 | 2 | 0.090 |
Why?
|
| India | 2 | 2023 | 13 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 112 | 0.090 |
Why?
|
| Child | 2 | 2025 | 524 | 0.090 |
Why?
|
| Demography | 2 | 2023 | 26 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2022 | 285 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 155 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2018 | 108 | 0.060 |
Why?
|
| Macular Edema | 2 | 2018 | 9 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 165 | 0.060 |
Why?
|
| Housing | 1 | 2026 | 6 | 0.060 |
Why?
|
| Hawaii | 2 | 2016 | 6 | 0.060 |
Why?
|
| Harm Reduction | 1 | 2025 | 3 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2018 | 500 | 0.060 |
Why?
|
| Sexual Harassment | 1 | 2025 | 1 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2026 | 197 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2025 | 46 | 0.060 |
Why?
|
| Oregon | 1 | 2024 | 2 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 82 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 46 | 0.050 |
Why?
|
| Emtricitabine | 1 | 2024 | 6 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 25 | 0.050 |
Why?
|
| Health Education | 1 | 2024 | 55 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 497 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 11 | 0.050 |
Why?
|
| Tobacco Products | 1 | 2023 | 14 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 16 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 61 | 0.050 |
Why?
|
| Family Planning Services | 1 | 2022 | 4 | 0.050 |
Why?
|
| Decision Making | 1 | 2022 | 25 | 0.050 |
Why?
|
| Trust | 1 | 2022 | 33 | 0.050 |
Why?
|
| Needle Sharing | 1 | 2022 | 1 | 0.050 |
Why?
|
| Coitus | 1 | 2022 | 9 | 0.050 |
Why?
|
| Disclosure | 1 | 2021 | 3 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 8 | 0.040 |
Why?
|
| Data Collection | 1 | 2021 | 38 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 1 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 128 | 0.040 |
Why?
|
| Malawi | 1 | 2020 | 3 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 6 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 8 | 0.040 |
Why?
|
| Consumer Behavior | 1 | 2019 | 4 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 10 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 49 | 0.040 |
Why?
|
| Injections | 1 | 2019 | 20 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 101 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 75 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2019 | 65 | 0.040 |
Why?
|
| Injection Site Reaction | 1 | 2018 | 2 | 0.040 |
Why?
|
| Methamphetamine | 1 | 2018 | 6 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 2018 | 5 | 0.040 |
Why?
|
| Health Services | 1 | 2018 | 12 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 16 | 0.040 |
Why?
|
| Sex Work | 1 | 2018 | 10 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2018 | 18 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2018 | 21 | 0.030 |
Why?
|
| Maryland | 1 | 2018 | 1 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2018 | 3 | 0.030 |
Why?
|
| Colorado | 1 | 2018 | 3 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2018 | 13 | 0.030 |
Why?
|
| Income | 1 | 2018 | 30 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 77 | 0.030 |
Why?
|
| Condoms | 1 | 2018 | 41 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 48 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 147 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 23 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 57 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 79 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 258 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 45 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 44 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 321 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 50 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 197 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 7 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 8 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 82 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 81 | 0.030 |
Why?
|